| Type | Public (NYSE: RMD) (ASX:RMD) |
|---|---|
| Industry | Medical |
| Founded | 1989 |
| Headquarters | San Diego, California |
| Key people | Peter C. Farrell, Founder, CEO and Chairman. |
| Products | Medical equipment for sleep-disordered breathing and other respiratory disorders |
| Website | www.resmed.com |
Founded in Australia, ResMed is now a global manufacturer of products for the treatment of sleep disorders, particularly obstructive sleep apnea (OSA). ResMed employs about 2700 employees worldwide, it has direct operations in 18 countries and distribution in more than 50 countries. In the fiscal year 2007/2008 it achieved revenues of US$ 800 million.[1]
ResMed considers the OSA market as underpenetrated and recently joined a partnership with LifeScan, a Johnson & Johnson company to increase awareness for OSA amongst type 2 diabetes patients.
ResMed was formed in 1989, its primary purpose was to commercialise a device for treating obstructive sleep apnea with nasal continuous positive airway pressure (CPAP). CPAP treatment was commercialised by Peter Farrell and Professor Colin Sullivan. The company grew organically and through several acquisitions of small companies active in ventilation.[1]